AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $251.23
- 52-wk high
- $267.47
- High
- $255.31
- 52-wk low
- $189.40
- Low
- $249.74
- Prev close
- $255.00
- Mkt cap
- $450.61B
- P/E
- 70.8x
- Volume
- 4.39M
- Fwd P/E
- 15.5x
- Beta
- 0.28
- Div yield
- 2.72%
- P/S
- 7.0x
- P/B
- 50.5x
- Profit margin
- +9.8%
- Op margin
- +40.0%
- ROE
- +62.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and 1 fin-fluencer is discussing it.
What funds are doing
Earnings
Earnings landed in line with what analysts expected.
Earnings per share
$3.64 expected
Revenue
$16.76B expected
GAAP EPS was $2.03; adjusted EPS matches the analyst basis.
Reports Oct 30, 2026, in 48 days
EPS expected
$3.77 to $3.87
Revenue expected
18 analysts
Last 30 days
Split both ways
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $15.78B | $16.62B | $15.00B | $16.99B |
| Cost of what it sold | $5.30B | $4.55B | $4.22B | $4.29B |
| Gross profit | $10.47B | $12.07B | $10.78B | $12.70B |
| What it spent | ||||
| Research and development | $2.32B | $2.58B | $2.47B | $2.34B |
| Sales and admin | $3.57B | $3.90B | $3.58B | $3.63B |
| Other operating costs | $2.68B | -$217.0M | — | $291.0M |
| Total operating expenses | $8.57B | $6.26B | $6.05B | $6.27B |
| What was left | ||||
| Operating profit | $1.90B | $5.81B | $4.73B | $6.43B |
| Interest on debt | $739.0M | $714.0M | $717.0M | $746.0M |
| Profit before tax | $714.0M | $2.67B | $1.04B | $4.28B |
| Tax | $526.0M | $853.0M | $342.0M | $662.0M |
| Net profit | $186.0M | $1.82B | $699.0M | $3.61B |
| EBITDA | $3.52B | $5.37B | $3.69B | $8.66B |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
AbbVie Gains as Qulipta Opens a New Migraine Market
BullishSep 10Abbvie Declares Quarterly Dividend, Payable on November 16, 2026
BullishSep 10AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Leans bullishSep 10AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
BullishSep 10AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days
NeutralSep 10AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
BullishSep 10AbbVie's menstrual migraine treatment meets late-stage study goal
BullishSep 10AbbVie’s migraine treatment meets late-stage study goal
BullishSep 10
Macro
31 macro signals shaping ABBV right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results